<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The early metabolic events in 33 patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were analyzed in the present study </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-three patients had Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3 had non-Burkitt undifferentiated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 7 had lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients developed <z:hpo ids='HP_0002157'>azotemia</z:hpo> prior to starting chemotherapy while five did so during the first treatment week </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients but two who developed <z:hpo ids='HP_0002157'>azotemia</z:hpo> had stage C or D disease </plain></SENT>
<SENT sid="4" pm="."><plain>Serum LDH prior to chemotherapy correlated well with the stage of disease and predicted the serum levels of <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:chebi fb="3" ids="27226">uric acid</z:chebi> and <z:chebi fb="81" ids="28659,35895">phosphorus</z:chebi> in the post-treatment period </plain></SENT>
<SENT sid="5" pm="."><plain>Surgical excision of the main <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass was associated with a low incidence of <z:hpo ids='HP_0002157'>azotemia</z:hpo> and other metabolic derangements </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002149'>Hyperuricemia</z:hpo> and occasionally obstruction were encountered as the causes of <z:hpo ids='HP_0002157'>azotemia</z:hpo> in the pre-treatment period </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002149'>Hyperuricemia</z:hpo> and/or <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> were presumed responsible for the development of <z:hpo ids='HP_0002157'>azotemia</z:hpo> in the post-chemotherapy period </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients were dialyzed for <z:hpo ids='HP_0000083'>renal failure</z:hpo> due to <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> and one for <z:hpo ids='HP_0000083'>renal failure</z:hpo> due to <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> which developed shortly after starting chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>The patterns of renal and metabolic disturbances observed during treatment of these patients were characterized by the following profiles: 1 </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0002157'>Azotemia</z:hpo> due to <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> prior to treatment </plain></SENT>
<SENT sid="11" pm="."><plain>2 </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0002149'>Hyperuricemia</z:hpo> without <z:hpo ids='HP_0002157'>azotemia</z:hpo> in the pre-treatment period with <z:hpo ids='HP_0002157'>azotemia</z:hpo> due to <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> in the post-treatment period </plain></SENT>
<SENT sid="13" pm="."><plain>3 </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0002157'>Azotemia</z:hpo> due to combined <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo> and <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> developing gradually in post-treatment period </plain></SENT>
<SENT sid="15" pm="."><plain>4 </plain></SENT>
<SENT sid="16" pm="."><plain>Increased urine <z:chebi fb="81" ids="28659,35895">phosphorus</z:chebi> excretion in both non-azotemic and azotemic patients </plain></SENT>
</text></document>